Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
190ATSE Growth

Chordia Therapeutics Inc.

Ｃｈｏｒｄｉａ　Ｔｈｅｒａｐｅｕｔｉｃｓ Yahoo Finance

Recent & upcoming events

Jul 15
Earnings 2:00
Q3 earnings announcement (scheduled)
Add to Google Calendar
Apr 14
Earnings 2:00
Q2 earnings announcement (scheduled)
Add to Google Calendar
Jan 14
Earnings 1:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
2025
Nov 24
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
Oct 15
Earnings 2:00 approx.
FY earnings announcement (scheduled)
Add to Google Calendar
2027
Jan 13
Est.
Earnings 1:00 approx.
Q1 earnings
Add to Google Calendar
Apr 14
Est.
Earnings 2:00 approx.
Q2 earnings
Add to Google Calendar
Jul 21
Est.
Earnings 2:00 approx.
Q3 earnings
Add to Google Calendar

KPI highlights

FY25
Revenue ¥0 YoY —
Operating income ¥-1.79B
Net income ¥-1.79B YoY —
EPS ¥-26 EPS is sourced from a different data provider than net income (for reference)
P/E —
ROE —

Company guidance

FY2026/08 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue — —
Operating income ¥-2.01B —
Net income ¥-1.96B —
EPS ¥-28 —

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q3FY24 Q2FY24 Q3
Revenue ¥0¥0¥0
Operating income ¥-524M¥-371M¥-621M
Net income ¥-525M¥-375M¥-650M
Operating CF ———

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2024–2025）

事業法人 17.5%国内機関 29.7%海外機関 7%その他 4.3%未開示 40%20242025
事業法人国内機関海外機関個人その他未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

武田薬品工業株式会社 15.6%武田薬品工業株式会社Ｎｅｗ Ｌｉｆｅ Ｓｃｉｅｎｃｅ 10.5%Ｎｅｗ Ｌｉｆｅ Ｓｃｉｅｎｃｅ１号投資事業有限責任組合日本グロースキャピタル投資法人 7%日本グロースキャピタル投資法人イノベーション京都２０１６投資事業有 6.8%イノベーション京都２０１６投資事業有限責任組合ＭＥＤＩＰＡＬ Ｉｎｎｏｖａｔｉｏ 6.1%ＭＥＤＩＰＡＬ Ｉｎｎｏｖａｔｉｏｎ投資事業有限責任組合三菱ＵＦＪライフサイエンス１号投 4.3%三菱ＵＦＪライフサイエンス１号投 資事業有限責任組合京大ベンチャーＮＶＣＣ２号投資事業有 3.7%京大ベンチャーＮＶＣＣ２号投資事業有限責任組合楽天証券株式会社 2.7%楽天証券株式会社株式会社メディパルホールディングス 1.9%株式会社メディパルホールディングス山田祥美 1.6%山田祥美20242025

Top shareholders — actual figures (as of 2025)

Holder Shares held Ratio Source
武田薬品工業株式会社 10,760,500 15.6% Yuho (EDINET)
Nｅｗ Lｉｆｅ Sｃｉｅｎｃｅ1号投資事業有限責任組合 7,252,100 10.5% Yuho (EDINET)
日本グロースキャピタル投資法人 4,810,500 7.0% Yuho (EDINET)
イノベーション京都2016投資事業有限責任組合 4,657,700 6.8% Yuho (EDINET)
MEDIPAL Iｎｎｏｖａｔｉｏｎ投資事業有限責任組合 4,210,800 6.1% Yuho (EDINET)
三菱UFJライフサイエンス1号投 資事業有限責任組合 2,971,700 4.3% Yuho (EDINET)
京大ベンチャーNVCC2号投資事業有限責任組合 2,570,900 3.7% Yuho (EDINET)
楽天証券株式会社 1,830,400 2.7% Yuho (EDINET)
株式会社メディパルホールディングス 1,307,100 1.9% Yuho (EDINET)
山田祥美 1,070,700 1.6% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

1/9 4 of 9 items lack data

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✗ Positive ROA ROA -66.6%
— Positive operating cash flow No data
✗ ROA improved YoY -39.4% → -66.6%
— Operating CF exceeds net income (accrual quality) No data
✓ Equity ratio improved* Substitute for the original “decrease in long-term debt” 89.8% → 90.9%
— Current ratio improved No data
✗ No dilution (shares outstanding did not increase) 67,678,800 → 68,988,800
— Gross margin improved No data
✗ Asset turnover improved 0.00× → 0.00×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY25
Equity ratio —
Current ratio —
Years of positive operating CF —
Payout ratio 0%
Latest fiscal year result Loss (net loss ¥1.79B)

Performance history

Last 10 years
0億円6億円13億円19億円25億円 FY21FY22FY23FY24FY25

Income & assets

Unit: ¥100M
Item FY21FY22FY23FY24FY25
Revenue 8.000.0025.00.000.00
Operating income -6.88-18.32.12-18.0-17.9
Ordinary income ———-18.2-17.7
Net income -5.27-17.82.23-18.3-17.9
Total assets ———46.326.8
Equity ———41.624.4

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Indicators & cash flow

Unit: ¥100M
Item FY21FY22FY23FY24FY25
EPS ¥-9—¥4¥-31¥-26
ROE —————
Operating CF —————
Investing CF —————
Financing CF —————
FCF —————

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data